Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Assets (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Assets for 16 consecutive years, with $80.1 million as the latest value for Q4 2025.

  • Quarterly Assets fell 36.77% to $80.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $80.1 million through Dec 2025, down 36.77% year-over-year, with the annual reading at $80.1 million for FY2025, 36.77% down from the prior year.
  • Assets for Q4 2025 was $80.1 million at Harvard Bioscience, up from $78.0 million in the prior quarter.
  • The five-year high for Assets was $162.3 million in Q4 2021, with the low at $78.0 million in Q3 2025.
  • Average Assets over 5 years is $131.5 million, with a median of $141.3 million recorded in 2023.
  • The sharpest move saw Assets rose 4.49% in 2022, then tumbled 40.57% in 2025.
  • Over 5 years, Assets stood at $162.3 million in 2021, then fell by 10.46% to $145.4 million in 2022, then dropped by 5.5% to $137.4 million in 2023, then fell by 7.81% to $126.6 million in 2024, then plummeted by 36.77% to $80.1 million in 2025.
  • According to Business Quant data, Assets over the past three periods came in at $80.1 million, $78.0 million, and $80.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.